

PANRETIN (alitretinoin 0.1% gel)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20, 2/2/21,
8/3/21, 2/1/22, 1/31/23, 2/13/24, 2/18/25

Panretin is a naturally occurring retinoid related to vitamin A that activates processes which regulate cell differentiation and proliferation in normal and neoplastic cells—inhibiting the growth of Kaposi sarcoma.

Authorization:

Topical treatment of cutaneous lesions in AIDS-related Kaposi sarcoma (KS).

NOTE: not indicated when systemic therapy for KS is necessary (eg, >10 new lesions in previous month, symptomatic visceral involvement, symptomatic pulmonary KS, symptomatic lymphedema). There is no experience in using alitretinoin (topical) in combination with systemic treatment for KS.

NOTE: Alitretinoin (topical) may be confused with tretinoin (topical)

Dosing Apply gel twice daily to cutaneous lesions; may gradually increase application frequency to 3 or 4 times daily based on lesion tolerance. Continue as long as deriving clinical benefit; response may be observed within 2 weeks of initiation; however, most patients require a longer period, and further benefit may be attained with a longer application period (>14 weeks) in some patients. avoid normal skin and mucosal surfaces; avoid occlusive dressings

PRECAUTIONS: photosensitivity; irritation to normal skin; extreme reaction of the lesions (pain, exfoliation, paresthesias)

DRUG INTERACTIONS: concomitant use of DEET-containing preparations (increased DEET toxicity)

REFERENCES

Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous kaposi sarcoma with topical alitretinoin (9-cis-retinoic acid) J Acquir Immune Defic Syndr. 1999;22(3):235–246.

Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related kaposi sarcoma using alitretinoin gel. Results of phase 1 and 2 trials. Arch Dermatol. 2000;136(12):1461–1469.

Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated kaposi's sarcoma. AIDS. 2002;16(3):421–429.

Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R. for The International Panretin® Gel KS study group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77–87. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17(3):437–443.

Panretin (alitretinoin) [prescribing information]. San Antonio, TX: DPT Laboratories, Ltd; received September 2019.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/2/21

Date Reviewed/Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 8/3/21

Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/1/22

Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/31/23

Date Reviewed/No Updates: 2/13/24 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/13/24.

Date Reviewed/Updated: 2/18/25 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/25

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/2/21	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated drug interactions and references. Formatting changes
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/18/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated description, authorization and dosing sections